Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPLE-Moderate: Remdesivir in Moderate COVID-19
NCT04292730Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical Status Assessed by a 7-Point Ordinal Scale at Day 11. Started Mar 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04292730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292730.